217 related articles for article (PubMed ID: 1346801)
1. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
2. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
Piro LD; Carrera CJ; Carson DA; Beutler E
N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
[TBL] [Abstract][Full Text] [Related]
3. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592
[No Abstract] [Full Text] [Related]
4. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
[TBL] [Abstract][Full Text] [Related]
5. 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma.
Betticher DC; Zucca E; von Rohr A; Egger T; Radford JA; Ambrosetti A; Bürki K; Rufener B; Schmitz SF; Cerny T
Ann Oncol; 1996 Oct; 7(8):793-9. PubMed ID: 8922192
[TBL] [Abstract][Full Text] [Related]
6. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Juliusson G; Elmhorn-Rosenborg A; Liliemark J
N Engl J Med; 1992 Oct; 327(15):1056-61. PubMed ID: 1355853
[TBL] [Abstract][Full Text] [Related]
7. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Saven A; Emanuele S; Kosty M; Koziol J; Ellison D; Piro L
Blood; 1995 Sep; 86(5):1710-6. PubMed ID: 7655003
[TBL] [Abstract][Full Text] [Related]
8. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
[TBL] [Abstract][Full Text] [Related]
9. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
Saven A; Carrera CJ; Carson DA; Beutler E; Piro LD
Blood; 1992 Aug; 80(3):587-92. PubMed ID: 1353380
[TBL] [Abstract][Full Text] [Related]
10. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
Morton J; Taylor K; Bunce I; Eliadis P; Rentoul A; Moore D; Kelly C; Wright S; Bashford J; Rodwell R; Rooney K; Mulligan S; Firkin F; Dodds A; Parkin J; Lowenthal R; Kimber R; Frost T; Grigg A; Goldstein D; Stone J; Lee N
Br J Haematol; 1996 Oct; 95(1):110-5. PubMed ID: 8857946
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
Tefferi A; Witzig TE; Reid JM; Li CY; Ames MM
J Clin Oncol; 1994 Mar; 12(3):569-74. PubMed ID: 8120555
[TBL] [Abstract][Full Text] [Related]
12. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
[TBL] [Abstract][Full Text] [Related]
13. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
Canfield VA; Vose J; Guiney P; Bennett B; Nichols C
Leuk Lymphoma; 1997 Jan; 24(3-4):335-9. PubMed ID: 9156663
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
[TBL] [Abstract][Full Text] [Related]
15. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
16. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
[TBL] [Abstract][Full Text] [Related]
17. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
18. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
[TBL] [Abstract][Full Text] [Related]
19. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials referral resource. Clinical trials with 2-chlorodeoxyadenosine.
Cheson BD
Oncology (Williston Park); 1992 May; 6(5):95-8. PubMed ID: 1350917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
